TMPRSS2 protein expression in the prostate and prostate cancer is not primarily driven by androgen (IMAGE)

Xia & He Publishing Inc.

TMPRSS2 protein expression in the prostate and prostate cancer is not primarily driven by androgen

Caption

(a) Representative images of TMPRSS2 IHC of murine prostate glands (n = 18; 9 young and 9 old) treated with vehicle, enzalutamide for 1 week, or enzalutamide for 2 weeks (n = 3 each), respectively. (b) Representative images of TMPRSS2 IHC of murine prostate glands (n = 8) treated with vehicle (n = 4), enzalutamide (n = 2), or abiraterone (n = 2), respectively. (c) Western blots of LNCaP and 16D cells treated with castration, enzalutamide (Enza), or Apalutamide (Apa), demonstrating the expression of TMPRSS2, PSA, and the loading control vinculin. (d) Quantification of RNA sequencing data (TPM) demonstrated reduced mRNA levels of KLK3 (PSA) and TMPRSS2 in 16D cells treated with vehicle or enzalutamide for 48 h. Data represent the unpaired t test with Welch’s correction. ***p < 0.001, **p < 0.01. (e, f) Representative images of TMPRSS2 IHC of LNCaP xenografts (e) (n = 2 each) and a patient-derived xenograft (f) at precastration, 7 days post castration, or 7 days post castration + enzalutamide treatment, respectively (n = 2 each). IHC, immunohistochemistry; KLK3, kallikrein 3; PSA, prostate-specific antigen; TMPRSS2, transmembrane serine protease 2.

Credit

Huihui Ye, Rong Rong Huang

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted.

License

CC BY-NC

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.